MapLight Therapeutics, Inc. MPLT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Business | ||||||
| All Other Segments | $933K+22.6% | $1.11M-50.5% | $1.17M+146% | $2.1M— | $761K— | |
| Chemistry Manufacturing And Controls Expenses | $6.42M+62.2% | —— | —— | —— | $3.96M+37.9% | |
| Clinical Trial | $24.82M+1,180% | $23.59M+387% | $11.92M+205% | $16.02M— | $1.94M— | |
| Employee Related | $15.99M+127% | $30.01M+398% | $7.04M+25.3% | $6.96M— | $7.05M— | |
| Preclinical Program | $5.52M-9.2% | $3.38M-29.8% | $2.79M-19.3% | —— | $6.08M— | |
| General And Administrative Expense by Business | ||||||
| Employee Related | $6.99M+239% | $15.82M+744% | $1.9M-7.6% | $1.9M— | $2.06M— | |
| Professional Fees | $3.83M+126% | $2.93M+1,451% | $2.5M+23.8% | $1.92M— | $1.7M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does MapLight Therapeutics, Inc. break its business down?
- MapLight Therapeutics, Inc. (MPLT) reports research and development expense by business across 5 parts — All Other Segments, Chemistry Manufacturing And Controls Expenses, Clinical Trial, Employee Related and Preclinical Program. Each is extracted from the segment footnotes and tracked over time.
- Where does MapLight Therapeutics, Inc. 's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MapLight Therapeutics, Inc. 's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.